Zobrazeno 1 - 10
of 340
pro vyhledávání: '"anti-CGRP"'
Autor:
Yu-Chin An, Kuo-Sheng Hung, Chih-Sung Liang, Chia-Kuang Tsai, Chia-Lin Tsai, Sy-Jou Chen, Yu-Kai Lin, Guan-Yu Lin, Po-Kuan Yeh, Fu-Chi Yang
Publikováno v:
The Journal of Headache and Pain, Vol 25, Iss 1, Pp 1-13 (2024)
Abstract Background Anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies have emerged as promising therapeutic options for the treatment of chronic migraine. However, treatment response varies considerably among individuals, suggesting a
Externí odkaz:
https://doaj.org/article/1877751684d042a188b9f77f476ec004
Autor:
Deirdre M. Boucherie, Ruben Dammers, Arnaud Vincent, A. H. Jan Danser, Antoinette MaassenVanDenBrink
Publikováno v:
The Journal of Headache and Pain, Vol 25, Iss 1, Pp 1-11 (2024)
Abstract Background Orally administered second-generation gepants are effective for the treatment of migraine. The intranasal administration of the third-generation gepant zavegepant might have additional benefits including a rapid onset of action, b
Externí odkaz:
https://doaj.org/article/05f6db0a3047442a85aeee2d4265dc6d
Autor:
Paolo Manganotti, Manuela Deodato, Laura D’Acunto, Francesco Biaduzzini, Gabriele Garascia, Antonio Granato
Publikováno v:
Neurology International, Vol 16, Iss 4, Pp 673-688 (2024)
Background: the aim of this study was to investigate the neurophysiological effect of anti-CGRP monoclonal antibodies on central and peripheral levels in migraine patients. Methods: An observational cohort study in patients with migraine was performe
Externí odkaz:
https://doaj.org/article/3a60b960a8fc4ac286338d33ffafc661
Publikováno v:
Neurology and Therapy, Vol 13, Iss 3, Pp 697-714 (2024)
Abstract Introduction This analysis of two Japanese clinical trials evaluated efficacy and safety after galcanezumab (GMB) discontinuation in patients with episodic migraine (EM) and chronic migraine (CM). Methods Data were from a 6-month, randomized
Externí odkaz:
https://doaj.org/article/4702e88d1500476ab5dc92f3b3f58c4d
Publikováno v:
The Journal of Headache and Pain, Vol 25, Iss 1, Pp 1-16 (2024)
Abstract Background Migraine is a highly prevalent neurological disease with a substantial societal burden due to lost productivity. From a societal perspective, we assessed the cost-effectiveness of eptinezumab for the preventive treatment of migrai
Externí odkaz:
https://doaj.org/article/fca3cd0fb19d4594a041cd2b7b168b47
Publikováno v:
The Journal of Headache and Pain, Vol 25, Iss 1, Pp 1-11 (2024)
Abstract Background Chronic migraine is a highly debilitating condition that is often difficult to manage, particularly in the presence of medication overuse headache. Drugs targeting the calcitonin gene-related peptide (CGRP), or its receptor have s
Externí odkaz:
https://doaj.org/article/0d1127851ad6434ab15dd00a55e7544d
Publikováno v:
The Journal of Headache and Pain, Vol 25, Iss 1, Pp 1-13 (2024)
Abstract Background Clinical characteristics and treatment practice of patients with migraine in Japan in real-world setting have not been fully investigated. We conducted a retrospective cohort study using claims database to understand the clinical
Externí odkaz:
https://doaj.org/article/89da59081f1c4026bda12b1e8cd48324
Autor:
Patricia Pozo-Rosich, Messoud Ashina, Stewart J. Tepper, Sidsel Jensen, Line Pickering Boserup, Mette Krog Josiassen, Bjørn Sperling
Publikováno v:
Neurology and Therapy, Vol 13, Iss 2, Pp 339-353 (2024)
Abstract Introduction In the DELIVER study, eptinezumab reduced monthly migraine days (MMDs) more than placebo in patients with 2–4 prior preventive migraine treatment failures. This post hoc analysis evaluated the efficacy of eptinezumab across th
Externí odkaz:
https://doaj.org/article/db3613d3bbe843fc9dda99c7098d8dd2
Autor:
Shengyuan Yu, Jiying Zhou, Guogang Luo, Zheman Xiao, Anders Ettrup, Gary Jansson, Ioana Florea, Kristina Ranc, Patricia Pozo-Rosich
Publikováno v:
BMC Neurology, Vol 23, Iss 1, Pp 1-14 (2023)
Abstract Background For some people with migraine, despite taking greater amounts of acute headache medication (AHM), they develop an increase in monthly headache days. This cycle of increasing headache days, and in turn AHM use, can lead to a second
Externí odkaz:
https://doaj.org/article/e9e9d427ec264f7f8d5d53e8c92478ce
Publikováno v:
Brain Sciences, Vol 14, Iss 9, p 948 (2024)
Background: The advent of monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway has transformed the management of migraine, offering newfound optimism for clinicians and individuals with episodic migraine (EM) and
Externí odkaz:
https://doaj.org/article/d0fc307d3d21459dbe8b4030316997ca